公开(公告)号：US20140113914A1

公开(公告)日：2014-04-24

申请号：US13657001

申请日：2012-10-22

Applicant: NOVARTIS AG

Inventor： Gurdip BHALAY ,  Lee EDWARDS ,  Catherine HOWSHAM ,  Peter HUNT ,  Nichola SMITH

IPC: C07D471/10 ,  A61P11/00 ,  A61K31/497

CPC classification number: A61K31/497 ,  C07D471/10

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract translation: 式I化合物及其药学上可接受的盐和溶剂合物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9和R10具有说明书中所示的含义，可用于治疗由 阻断上皮钠通道。 还描述了含有化合物的药物组合物和用于制备化合物的方法。

公开(公告)号：US20210228554A1

公开(公告)日：2021-07-29

申请号：US17221555

申请日：2021-04-02

Applicant: Novartis AG

Inventor： Urs BAETTIG ,  Kamlesh Jagdis BALA ,  Emma BUDD ,  Lee EDWARDS ,  Catherine HOWSHAM ,  Glyn Alan HUGHES ,  Darren Mark LE GRAND ,  Katrin SPIEGEL

IPC: A61K31/44 ,  A61K31/4418 ,  C07D213/81 ,  C07D401/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5377 ,  C07D213/38 ,  C07D401/12 ,  C07D403/12 ,  A61K31/4412 ,  A61K45/06 ,  C07D405/04 ,  C07D241/26

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

公开(公告)号：US20170143705A1

公开(公告)日：2017-05-25

申请号：US15369133

申请日：2016-12-05

Applicant: NOVARTIS AG

Inventor： Gurdip BHALAY ,  Lee EDWARDS ,  Catherine HOWSHAM ,  Peter HUNT ,  Nichola SMITH

IPC: A61K31/497

CPC classification number: A61K31/497 ,  C07D471/10

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

公开(公告)号：US20150224098A1

公开(公告)日：2015-08-13

申请号：US14690513

申请日：2015-04-20

Applicant: NOVARTIS AG

Inventor： Gurdip BHALAY ,  Lee EDWARDS ,  Catherine HOWSHAM ,  Peter HUNT ,  Nichola SMITH

IPC: A61K31/497

CPC classification number: A61K31/497 ,  C07D471/10

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract translation: 式I化合物及其药学上可接受的盐和溶剂合物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9和R10具有说明书中所示的含义，可用于治疗由 阻断上皮钠通道。 还描述了含有化合物的药物组合物和用于制备化合物的方法。